📅 2026년 5월 27일 | PubMed 수집 논문 ★ 주요 논문 — 이번 수집의 하이라이트 Safety, efficacy, and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B. (2026-05-26) Fidanacogene elaparvovec is a single-dose gene therapy designed to express the high-activity factor IX (FIX) variant FIX-R338L. Participants (N = 15) with FIX activity…
📅 2026년 5월 27일 | PubMed 수집 논문 ★ 주요 논문 — 이번 수집의 하이라이트 Safety, efficacy, and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B. (2026-05-26) Fidanacogene elaparvovec is a single-dose gene therapy designed to express the high-activity factor IX (FIX) variant FIX-R338L. Participants (N = 15) with FIX activity…
📅 2026년 5월 27일 | PubMed 수집 논문 ★ 주요 논문 — 이번 수집의 하이라이트 Safety, efficacy, and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B. (2026-05-26) Fidanacogene elaparvovec is a single-dose gene therapy designed to express the high-activity factor IX (FIX) variant FIX-R338L. Participants (N = 15) with FIX activity…
📅 2026년 5월 27일 | PubMed 수집 논문 ★ 주요 논문 — 이번 수집의 하이라이트 Safety, efficacy, and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B. (2026-05-26) Fidanacogene elaparvovec is a single-dose gene therapy designed to express the high-activity factor IX (FIX) variant FIX-R338L. Participants (N = 15) with FIX activity…
📅 2026년 5월 27일 | PubMed 수집 논문 ★ 주요 논문 — 이번 수집의 하이라이트 Safety, efficacy, and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B. (2026-05-26) Fidanacogene elaparvovec is a single-dose gene therapy designed to express the high-activity factor IX (FIX) variant FIX-R338L. Participants (N = 15) with FIX activity…
